[Involvement of glial glutamate transporters in morphine dependence and naloxone-precipitated withdrawal].
A body of evidence supports that excitatory amino acid systems, particularly glutamatergic one, participate in morphine dependence and naloxone-precipitated withdrawal. In this study, we examined the involvement of glial glutamate transporters, GLT-1 and GLAST, in them. Rats were rendered morphine-dependent by subcutaneous implantation of two 75 mg morphine pellets for 5 days. Intracerebroventricular administration of DL-threo-beta-benzyloxyaspartate, a glutamate transporter inhibitor significantly facilitated various naloxone-precipitated withdrawal signs. By northern blot analysis, the expression of GLT-1 mRNA was found to decrease significantly in the striatum and thalamus of morphine-dependent rats, and to increase significantly in the striatum 2 hr after the naloxone-precipitated withdrawal. On the other hand, there were no significant changes in GLAST mRNA levels in any brain regions. In vivo microdialysis experiments revealed that the extracellular glutamate levels was elevated in the striatum and nucleus accumbens, in which the changes of GLT-1 mRNA level were observed, during naloxone-precipitated morphine withdrawal. In cultured astrocytes, the expression of GLT-1 mRNA was regulated by agents activating the cAMP pathway, as well as beta-adrenergic agonist and dopamine, but not morphine. These results suggest that the changes of GLT-1 expression, which alter the glutamate uptake and affect the glutamatergic transmission efficiency, play a role in the development of morphine dependence and the expression of morphine withdrawal.
Nakagawa
T
T
Faculty of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan.
D027322:Amino Acid Transport System X-AG / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D000818:Animals; D001224:Aspartic Acid / Q000494:pharmacology; D001253:Astrocytes / Q000378:metabolism; D001921:Brain / Q000378:metabolism; D002478:Cells, Cultured; D027342:Excitatory Amino Acid Transporter 2 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology; D015870:Gene Expression; D006801:Humans; D009021:Morphine Dependence / Q000209:etiology*; D009270:Naloxone / Q000009:adverse effects*; D012333:RNA, Messenger / Q000378:metabolism; D013375:Substance Withdrawal Syndrome / Q000209:etiology*
D027322:Amino Acid Transport System X-AG; D027342:Excitatory Amino Acid Transporter 2; D012333:RNA, Messenger; C120673:benzyloxyaspartate; D001224:Aspartic Acid; D009270:Naloxone